Oticon Introduces Oticon More

Oticon, Inc. is challenging the conventions of hearing aid technology once again. The company today launched Oticon More ™, the first-ever hearing aid built with an on-board deep neural network, to give people with mild-to-severe hearing loss a fuller, more balanced and more effortless hearing experience.

The DNN in Oticon More is trained on 12 million real-life sounds to give the brain more of the information it needs to decipher the intricate details of sound. Based on this extensive experiential learning – not on a limited set of man-made rules – it processes speech in noise more like the human brain. This results in a more natural representation of sounds that improves wearers’ speech understanding, reduces listening effort and enables people with hearing loss to remember more of what is being said, even in noisy environments.

“With Oticon More, wearers receive a more natural representation of all sounds,” says Donald Schum, Ph.D., Vice President of Audiology, Oticon, Inc. “The DNN in Oticon More has learned the way the brain learns, naturally over time. Every sound that passes through the hearing aid is compared to the results discovered in the learning phase. This enables Oticon More to provide a more natural, full and precisely balanced sound scene, making it easier for the brain to perform optimally.”

Powerful, more intelligent sound processing

Oticon More with BrainHearing™ technology delivers what the brain needs to make better sense of sound. Built on Oticon’s most intelligent platform yet, Oticon More provides 30% more sound to the brain and improves speech understanding by 15%.*

Industry-leading innovation in sound processing technology ensures Oticon More delivers the information wearers need to decipher sounds and fully engage in any conversation. The hearing aid scans and analyzes the sound scene 500 times per second, capturing and processing the intricate details of sound with better contrast, balance and clarity than ever before.

Oticon More builds on Oticon’s legacy of award-winning product innovation and industry firsts. The hearing aid was recently named a CES® 2021 Innovation Awards Honoree in the Health & Wellness and Wearable Technologies categories.

Connectivity and convenience

Oticon More offers a wide range of connectivity options for a high-quality listening experience in everyday situations. The hearing aid supports direct streaming from iPhone® and select Android™ devices. For people who want the convenience of rechargeable batteries, Oticon More comes in a discreet lithium-ion based rechargeable style (miniRITE R) that provides a full day of battery life**, including streaming, after just three hours of charging.

The new hearing solution is built for individuals with mild-to-severe hearing loss. Wearers can select from eight attractive colors to blend with hair or skin tones.

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.